Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 1:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hepatitis C Virus (HCV)
Interventions
Pegylated interferon lambda (pegIFNλ), Pegylated interferon alfa-2a (pegIFNα-2a), Ribavirin, Daclatasvir, Placebo matching Daclatasvir
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
18
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 12 more
Conditions
Hepatitis C
Interventions
Daclatasvir, Asunaprevir, BMS-791325, Ribavirin, Placebo matching Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 22 more
Conditions
Hepatitis C
Interventions
INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anaheim, California • La Jolla, California • San Francisco, California + 3 more
Conditions
Chronic Hepatitis C
Interventions
Daclatasvir, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Anaheim, California • Cypress, California • New Haven, Connecticut + 4 more
Conditions
Hepatitis C
Interventions
BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more